-
BI 2536 for Reliable PLK1 Assays
2026-09-10
This scenario-driven guide explains how BI 2536 (SKU A3965) can improve interpretation of proliferation, viability, cell-cycle, and apoptosis experiments. It connects PLK1 biology with practical formulation, dosing, controls, and data-analysis decisions supported by product information and published research.
-
Pepstatin A Workflows for Protease Research
2026-09-10
Pepstatin A provides a focused way to interrogate pepsin, renin, HIV protease, and cathepsin D in biochemical and cell-based models. This practical guide connects stock preparation, potency-aware assay design, viral protein processing research, and osteoclast differentiation inhibition with orthogonal validation principles from a recent TET2 protocol.
-
DiscoveryProbe FDA-approved Drug Library: OA
2026-09-09
Use a clinically anchored compound collection to convert an osteoarthritis mechanism into a scalable screening workflow. The approach combines OSCAR-binding assays, chondrocyte phenotyping, high-content confirmation, and drug repositioning screening while preserving a clear path to target validation.
-
SHC-1 Inhibition and CFTR Membrane Trafficking
2026-09-09
A 2026 study shows that MAPK/SHC-1-dependent CFTR internalization is conserved across airway and intestinal epithelial models, while the effects of SHC-1 inhibitors on surface abundance are strongly cell-type dependent. The work identifies a potential trafficking mechanism relevant to CFTR-related disease but also cautions that CFBE cells may not fully represent endogenous epithelial regulation.
-
SU 5402 Workflows for RTK Signaling Research
2026-09-08
SU 5402 enables time-resolved interrogation of VEGFR2, FGFR1, PDGFRβ, and downstream ERK1/2–STAT3 signaling, with especially useful applications in FGFR3-dependent multiple myeloma models. This guide pairs validated oncology workflows with a carefully bounded, exploratory framework for human iPSC-derived sensory-neuron studies.
-
Drug Response Assays: Insights from Schwartz (2022)
2026-09-08
Hannah Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central practical contribution is a framework for separating growth inhibition from cell killing across dose and time, improving interpretation of in vitro pharmacology experiments.
-
3X FLAG peptide Workflows for NLRP3 Studies
2026-09-07
The 3X (DYKDDDDK) Peptide turns FLAG-tagged expression constructs into practical tools for selective capture, immunodetection, and structural sample preparation. Applied to full-length NLRP3, it supports a workflow that preserves native oligomeric states while exposing aggregation, metal sensitivity, and tag-accessibility problems early.
-
CHIR-99021 (CT99021): From Wnt Control to Translation
2026-09-05
CHIR-99021 (CT99021) is more than a routine GSK-3 inhibitor: it is a strategic perturbation tool for testing how receptor-level Wnt antagonism, β-catenin stability, pluripotency, and lineage commitment interact. This thought-leadership guide connects mechanism, experimental design, product selection, and translational decision-making.
-
STNvac mRNA Vaccine Drives TLS Formation in HCC
2026-09-05
Lin et al. developed a spleen-targeted neoantigen mRNA vaccine, STNvac, that produced strong antitumor activity in orthotopic hepatocellular carcinoma models and was associated with improved survival. The study links this response to neoantigen-specific ISG15-positive CD8-positive T cells, GZMA-F2R signaling with antigen-presenting cells, and tertiary lymphoid structure formation.
-
Sphingosine-1-phosphate Assay Workflows
2026-09-04
Build receptor-aware S1P experiments for endothelial, survival, and neuronal apoptosis models. This workflow combines fresh-solution handling, concentration-response design, orthogonal readouts, and the S1PR3 findings reported after intracerebral hemorrhage.
-
MTT Assays as a Lens on Drug Resistance
2026-09-04
MTT transforms cellular reducing activity into a practical readout for proliferation and drug response. This evidence-focused guide explains how to interpret the assay in cisplatin-resistant ovarian cancer models without confusing metabolic signal with cell number or mechanism.
-
Amikacin Sulfate: From Mechanism to Translation
2026-09-03
Amikacin Sulfate is more than a conventional aminoglycoside benchmark: its translational value depends on connecting ribosomal mechanism, intracellular exposure, granuloma-directed delivery, and function-first microbiology. This article outlines a practical strategy for using Amikacin to generate more predictive non-tuberculous mycobacterial research data.
-
Antipyrine in BBB Permeability Research
2026-09-03
Antipyrine offers a highly soluble, high-purity test compound for linking pain and fever pharmacology with practical blood-brain barrier transport workflows. This guide shows how to use it as a carefully controlled comparator in LLC-PK1-MOCK/MDR1 assays while avoiding false conclusions caused by solvent effects, transporter activity, or lysosomal trapping.
-
Cinoxacin Workflows for Gram-Negative Research
2026-09-02
Cinoxacin provides a practical, mechanism-informed benchmark for urinary tract infection research, susceptibility testing, and resistance experiments involving susceptible Gram-negative organisms. This guide combines formulation guidance, assay-ready parameters, comparative interpretation, and a precision-trial framework for generating more reproducible antimicrobial data.
-
Cyanine 3 Tyramide in Neuroscience TSA
2026-09-02
Cyanine 3 Tyramide is an orange fluorescent dye for biomedical research that supports enzyme-mediated signal enhancement in tissue and molecular assays. Its strongest value in early-life-adversity studies is sensitive spatial visualization, while causal conclusions still require independent circuit and behavioral experiments.